Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
Devos G, Tosco L, Baldewijns M, Gevaert T, Goffin K, Petit V, Mai C, Laenen A, Raskin Y, Van Haute C, Goeman L, De Meerleer G, Berghen C, Devlies W, Claessens F, Van Poppel H, Everaerts W, Joniau S. Devos G, et al. Among authors: devlies w. Eur Urol. 2023 Jun;83(6):508-518. doi: 10.1016/j.eururo.2022.09.009. Epub 2022 Sep 24. Eur Urol. 2023. PMID: 36167599 Clinical Trial.
Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by 68Ga-PSMA-11 PET/CT or 11C-Choline PET/CT: impact of postoperative treatments.
Devos G, Witters M, Moris L, Van den Broeck T, Berghen C, Devlies W, De Meerleer G, Goffin K, Jentjens S, Albersen M, Van Poppel H, Everaerts W, Joniau S. Devos G, et al. Among authors: devlies w. World J Urol. 2021 Feb;39(2):399-406. doi: 10.1007/s00345-020-03220-0. Epub 2020 May 16. World J Urol. 2021. PMID: 32417995
Current and emerging therapies for localized high-risk prostate cancer.
Moris L, Devos G, Van den Broeck T, Milonas D, Albersen M, Berghen C, De Meerleer G, Devlies W, Everaerts W, Gevaert T, Van Poppel H, Claessens F, Joniau S. Moris L, et al. Among authors: devlies w. Expert Rev Anticancer Ther. 2021 Mar;21(3):267-282. doi: 10.1080/14737140.2021.1852932. Epub 2020 Dec 22. Expert Rev Anticancer Ther. 2021. PMID: 33225759 Review.
Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer.
Devos G, Devlies W, De Meerleer G, Baldewijns M, Gevaert T, Moris L, Milonas D, Van Poppel H, Berghen C, Everaerts W, Claessens F, Joniau S. Devos G, et al. Among authors: devlies w. Nat Rev Urol. 2021 Dec;18(12):739-762. doi: 10.1038/s41585-021-00514-9. Epub 2021 Sep 15. Nat Rev Urol. 2021. PMID: 34526701 Review.
Antizyme Inhibitor 1 Regulates Matrikine Expression and Enhances the Metastatic Potential of Aggressive Primary Prostate Cancer.
Van den Broeck T, Moris L, Gevaert T, Davicioni E, Boeckx B, Lambrechts D, Helsen C, Handle F, Ghesquière B, Soenen S, Smeets E, Eerlings R, El Kharraz S, Devlies W, Karnes RJ, Lotan T, Van Poppel H, Joniau S, Claessens F. Van den Broeck T, et al. Among authors: devlies w. Mol Cancer Res. 2022 Apr 1;20(4):527-541. doi: 10.1158/1541-7786.MCR-21-0388. Mol Cancer Res. 2022. PMID: 35082164
27 results